Clarity Pharmaceuticals Ltd (CU6.AX)

5,42 +0,35 (+6,90%) Börsenschluss: 04:10PM AEST

Clarity Pharmaceuticals Ltd

National Innovation Centre
Suite 212a 2 4 Cornwallis Street Eveleigh
Sydney, NSW 2015
Australia
61 2 9209 4037
https://www.claritypharmaceuticals.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 41

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Alan John Taylor Ph.D.	Executive Chairman	847,36k	N/A	N/A
Dr. Colin David Biggin Ph.D.	MD, CEO & Executive Director	679,38k	N/A	N/A
Mr. David K. Green BEc., CA	Chief Financial Officer	237,8k	N/A	N/A
Mr. Shaemus Gleason	Executive Vice President of Operations	N/A	N/A	N/A
Dr. Matthew Harris BSc., M.B.A., Ph.D.	CTO & Director of Technology	195,43k	N/A	N/A
Dr. Jeffrey Norenberg	Chief Scientific Officer	N/A	N/A	N/A
Michelle Parker	Executive Vice President of Global Clinical Operations	N/A	N/A	N/A
Mr. Robert Vickery	Company Secretary	163,1k	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in AUD.

Beschreibung

Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults. Its lead product includes SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2. The company is also developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express gastrin releasing peptide receptor; and SAR-bisPSMA, a theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express prostate specific membrane antigen. Clarity Pharmaceuticals Ltd was incorporated in 2010 and is based in Sydney, Australia.

Corporate Governance

Clarity Pharmaceuticals Ltds ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.